BioCardia (BCDA) & Its Competitors Head to Head Contrast

BioCardia (NASDAQ:BCDA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare BioCardia to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for BioCardia and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1	1	1	0	2.00
BioCardia Competitors	9773	15031	45238	1571	2.54

BioCardia presently has a consensus target price of $25.00, indicating a potential upside of 2,803.60%. As a group, “Biotechnology” companies have a potential upside of 95.32%. Given BioCardia’s higher possible upside, research analysts clearly believe BioCardia is more favorable than its rivals.

Volatility & Risk

BioCardia has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, BioCardia’s rivals have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Insider & Institutional Ownership

20.6% of BioCardia shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares BioCardia and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioCardia	$60,000.00	-$8.23 million	-1.35
BioCardia Competitors	$689.45 million	$10.37 million	-10.05

BioCardia’s rivals have higher revenue and earnings than BioCardia. BioCardia is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares BioCardia and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
BioCardia Competitors	-9,054.31%	-198.21%	-30.53%

Summary

BioCardia rivals beat BioCardia on 9 of the 13 factors compared.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.